Benzinga | Nov 22, 2021 11:12AM EST

Expert Ratings For Alnylam Pharmaceuticals

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish BearishTotal Ratings 4 4 2 0 0Last 30D 2 1 0 0 01M Ago 1 2 1 0 02M Ago 1 1 0 0 03M Ago 0 0 1 0 0

In the last 3 months, 10 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $209.0 with a high of $273.00 and a low of $108.00.

Below is a summary of how these 10 analysts rated Alnylam Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This average price target has increased by 18.67% over the past month.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.